RxDoctor Payments Data

Aurelio Varona Berdial, MD

Internal Medicine · Miami, FLNPI 1659804458

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Johnson & Johnson at 35.3% of the total. 2025 is the largest year on record at $562, more than ten times the $23 reported in 2019.

$1,883in general payments, 2019–2025

Across 41 payments — averaging $45.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$665
  • Abbott$325
  • Atricure, Inc.$289
  • Penumbra, Inc.$143
  • AbbVie$141
  • Medtronic$97
  • plus $222 from 5 others
$111,778in research payments, 2019–2025

Across 17 payments — averaging $6575.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$94K
  • Sanofi US Services Inc.$18K

What the payments were for

  • Food & beverage$1,883100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,883 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida →

Medicare billing

Part B allowed, 2024
$84,368
Medicare patients
287
Services billed
764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$16,343
Cefdinir56$637
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav20$154
Atorvastatin Calcium54$145
Pantoprazole Sodium24$141
Levofloxacin40$131
Metoprolol Succinate27$130
Metronidazole16$104
Losartan Potassium20$102
ClopidogrelClopidogrel Bisulfate33$95
Doxycycline Hyclate16$53
Carvedilol21$49
Spironolactone15$37
Amlodipine Besylate24$28
Furosemide13$28

Paid to pharmacies, not to this prescriber.

Other internal medicine in Miami

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →